HEALTH.2013.1.3-3
HEALTH.2013.1.3-3
7 projects · €41,800,680 total EU contribution (project-level) · 50 participating organizations · 13 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€41,800,680
Countries active
Participant organizations by country (headquarters in CORDIS).
- BE (9)
- AT (8)
- Netherlands (7)
- France (5)
- Germany (4)
- Spain (4)
- UK (4)
- SE (3)
- DK (2)
- CH (1)
- FI (1)
- PL (1)
- US (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- INSERM3 projects · FR
- GSKBIO2 projects · BE
- INSERM TRANSFERT SA2 projects · FR
- AMC1 projects · NL
- Leiden University Medical Center1 projects · NL
- AEPODIA1 projects · BE
- AFFIRIS AG1 projects · AT
- ALL MED1 projects · PL
- API1 projects · BE
- ASPHALION1 projects · ES
- BIOL1 projects · AT
- BIOMAY1 projects · AT
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Reach α-synuclein-dependent neurodegeneration: clinical development of therapeutic AFFITOPE vaccines for Parkinson’s disease and multisystem atrophy SYMPATH · 602999 | FP7 | €5,999,706 | €7,699,474 | Details |
AN INNOVATIVE CAUSAL THERAPY FOR ALLERGY: SAFE AND RAPID INDUCTION OF AN ANTI-INFLAMMATORY IMMUNE RESPONSE USING A MUTANT HYPOALLERGEN AND VITAMIN D3 BM4SIT · 601763 | FP7 | €5,996,408 | €7,807,110 | Details |
Vaccination In Atherosclerosis VIA · 603131 | FP7 | €5,994,233 | €8,136,786 | Details |
Proposal to assess an innovative Immunotherapy, based on a thioredox peptide antigen, in a Phase I Trial for Type-1 Diabetes EXALT · 602515 | FP7 | €6,000,000 | €13,076,049 | Details |
Therapeutic TriMix / mRNA based Vaccine in Chronic HIV-1 Infected Patients Receiving Antiretroviral Therapy IHIVARNA · 602570 | FP7 | €5,984,720 | €7,826,907 | Details |
The development of a novel therapeutic vaccine for the selective treatment of the autoimmune disorder, Graves’ disease DAVIAD · 602779 | FP7 | €5,924,893 | €8,362,661 | Details |
Clinical safety, immunogenicity and efficacy of a therapeutic vaccine that combines peptides mimicking antigen receptors on autoimmune B and T cells associated with myasthenia gravis Myasterix · 602420 | FP7 | €5,900,720 | €7,538,399 | Details |